Perrigo (PRGO) just shifted out of the Russell 1000 and Midcap indices and into the Russell 2000 and related benchmarks, a reshuffle that can alter liquidity, investor mix, and short term trading behavior.

Perrigo's latest share price of $10.52 comes after a 1 day share price return that declined 5.99%, capping a 30 day share price return that fell 9.39% and contributing to year to date share price weakness of 24.26%. The 1 year total shareholder return declined 58.05%, pointing to fading momentum despite recent board refreshment and the index shift.

If Perrigo's index move has you reconsidering where you look for opportunities, this could be a useful moment to broaden your search and check out 19 top founder-led companies

Perrigo still runs a broad over the counter health and wellness business, but after the index reshuffle and recent share price slide, the real question is whether the stock now reflects that reality or misprices it.

Most Popular Narrative: 36.2% Undervalued

Compared with Perrigo's last close at $10.52, the most followed narrative places fair value at $16.50, framing the recent sell off as a sharp disconnect in pricing.

Recent new business wins in US store-brand OTC have outpaced distribution losses for the first time since the 2024 reset. Net new contract gains are expected to add $75M+ to sales in the second half, directly supporting a step-change in revenue growth and operating income.

Want to see how this contract pipeline feeds into Perrigo's valuation story? The narrative leans heavily on margin repair, modest revenue growth and a richer future profit multiple.

Result: Fair Value of $16.50 (UNDERVALUED)

However, Perrigo's narrative could be challenged if category consumption remains soft in key markets, or if infant formula share and margins struggle to recover as expected.

Next Steps

With mixed sentiment around Perrigo, this is a moment to move fast, review both sides of the story and weigh the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Perrigo?

If Perrigo has you rethinking your watchlist, do not stop here, broaden your research now so you are not late to the next opportunity.

• Spot potential value early by scanning companies that currently look mispriced using the 44 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses with stronger balance sheets through the solid balance sheet and fundamentals stocks screener (47 results).
• Hunt for future standouts by reviewing a curated screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.